Novo Nordisk to launch 10 new medicines in China by 2025-26
By Zheng Yiran | China Daily | Updated: 2018-10-09 07:36
Novo Nordisk, a global pharmaceuticals company known for its diabetes drugs, said it will introduce 10 innovative drugs in the Chinese market by 2025-26. It will also continue to invest in China for more treatment-related products.
Christine Zhou, president of Novo Nordisk China, the company's local unit, said: "There are about 61 million untreated diabetes patients in China and we are committed to addressing the increasing diabetes burden now and in the coming years.
"Novo Nordisk in China has a positive outlook and we will continue to explore opportunities to drive our leadership in the diabetes market, and accordingly we expect the organization will continue to expand, to help improve healthcare for diabetics in China."
Photo